Sonia D. Cohen

Surgical Oncology

55 Fruit St
Boston, MA 02114

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Frontline immunotherapy with response-guided subsequent treatment (FIRST) in cutaneous squamous cell carcinoma: a Bayesian causal analysis of dose intensity, early benefit, and treatment de-escalation.

Frontline immunotherapy with response-guided subsequent treatment (FIRST) in cutaneous squamous cell carcinoma: a Bayesian causal analysis of dose intensity, early benefit, and treatment de-escalation.

Journal: Journal for immunotherapy of cancer

Published: July 03, 2026

ASO Visual Abstract: Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response.

ASO Visual Abstract: Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response.

Journal: Annals of surgical oncology

Published: June 05, 2026

Cutaneous Eruptions and Lifileucel/Interleukin 2 in Individuals With Metastatic Melanoma.

Cutaneous Eruptions and Lifileucel/Interleukin 2 in Individuals With Metastatic Melanoma.

Journal: JAMA dermatology

Published: April 15, 2026

Biomarkers of Immunotherapy Response in Surgical Oncology.

Biomarkers of Immunotherapy Response in Surgical Oncology.

Journal: Surgical oncology clinics of North America

Published: March 28, 2026

The CD49b (ITGA2) collagen receptor excludes CD8+ T cell infiltration in pancreatic ductal adenocarcinoma.

The CD49b (ITGA2) collagen receptor excludes CD8+ T cell infiltration in pancreatic ductal adenocarcinoma.

Journal: iScience

Published: December 19, 2025

Overcoming impaired antigen presentation in tumor-draining lymph nodes facilitates immunotherapy.

Overcoming impaired antigen presentation in tumor-draining lymph nodes facilitates immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: December 15, 2025

Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response.

Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response.

Journal: Annals of surgical oncology

Published: December 03, 2025

Buoyant mass reveals distinct T cell states predictive of checkpoint response.

Buoyant mass reveals distinct T cell states predictive of checkpoint response.

Journal: bioRxiv : the preprint server for biology

Published: December 03, 2025

Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ TIL.

Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ TIL.

Journal: bioRxiv : the preprint server for biology

Published: December 03, 2025

Opportunities and challenges in the clinical application of anticancer virotherapy.

Opportunities and challenges in the clinical application of anticancer virotherapy.

Journal: Expert review of anticancer therapy

Published: November 01, 2025

Letter to the EditorTumor-infiltrating lymphocyte therapy generated from melanoma brain metastasis: Proof-of-concept for CNS-derived cellular immunotherapy.

Letter to the EditorTumor-infiltrating lymphocyte therapy generated from melanoma brain metastasis: Proof-of-concept for CNS-derived cellular immunotherapy.

Journal: Neuro-oncology

Published: October 30, 2025

The anti-virus T cell response dominates the anti-cancer response in oncolytic virus therapy.

The anti-virus T cell response dominates the anti-cancer response in oncolytic virus therapy.

Journal: bioRxiv : the preprint server for biology

Published: October 03, 2025

Showing 1-12 of 41

Last Updated: 09/26/2026